Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: A nationwide survey in Japan

Hematopoietic stem cell transplantation (HSCT) has not been indicated for patients with mucopolysaccharidosis II (MPS II, Hunter syndrome), while it is indicated for mucopolysaccharidosis I (MPS I) patients

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecular genetics and metabolism 2012-11, Vol.107 (3), p.513-520
Hauptverfasser: Tanaka, Akemi, Okuyama, Torayuki, Suzuki, Yasuyuki, Sakai, Norio, Takakura, Hiromitsu, Sawada, Tomo, Tanaka, Toju, Otomo, Takanobu, Ohashi, Toya, Ishige-Wada, Mika, Yabe, Hiromasa, Ohura, Toshihiro, Suzuki, Nobuhiro, Kato, Koji, Adachi, Souichi, Kobayashi, Ryoji, Mugishima, Hideo, Kato, Shunichi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Hematopoietic stem cell transplantation (HSCT) has not been indicated for patients with mucopolysaccharidosis II (MPS II, Hunter syndrome), while it is indicated for mucopolysaccharidosis I (MPS I) patients
ISSN:1096-7192
1096-7206
DOI:10.1016/j.ymgme.2012.09.004